Objective GI Funding Announcement
Objective GI Receives Venture Capital Funding to Expand Network of GI-specific Research Sites
The clinical research company establishes partnerships with gastroenterology practices and is forecasted to grow to more than 30 research sites across the U.S.
NASHVILLE, Tenn. – January 29, 2019 – Objective GI, a gastrointestinal-focused clinical research company, announces a key investment by TKS 1, a joint venture between SPRIM and Tikehau Capital, enabling the company to grow its network of GI-specialty clinical research sites in the United States. Objective GI improves research through an established network of partnerships with gastroenterology medical practices, providing research infrastructure, optimal trial selection, study implementation and key personnel management to clinical studies.
“This investment marks a major step forward for our company to leverage our research platform and strengthen our core offerings,” said Colleen Hoke, CEO of Objective GI. “We are focused on providing the most advanced research structure to enable leading partnered physician groups to enhance the quality and value of patient care through clinical research.”
Objective GI gives doctors access to the latest treatments, while offering patients access to optimal clinical trials and providing sponsors with superior patient enrollment, all with the objective to bring clinical care solutions to market as quickly as possible. The company is currently partnered with more than 60 gastroenterology providers at five sites across the U.S. and is forecasted to grow to more than 30 sites by the end of 2021.
This latest key investment in Objective GI comes from TKS 1, a venture capital collaboration between SPRIM and Tikehau Capital (TKO.FP), an alternative asset management and investment company. TKS 1 provides early-stage capital to innovative companies offering solutions that move science forward in the health sector, contribute to the transition from intervention to prediction while enabling life science companies globally to develop therapeutics faster and more economically.
“This investment means Objective GI can leverage the resources and expertise of SPRIM, a company with more than 20 years in the clinical research industry,” said Laurent Benissan, partner at SPRIM Ventures. “We’re excited to offer the funding and look forward to accelerated growth to the Objective GI infrastructure and network.”
SPRIM is a life-science consulting agency for the full lifecycle of a product. Multi-nationals, startups, institutions and governments around the world turn to SPRIM for expertise in developing relevant, fresh and meaningful health innovations. From traditional categories like nutrition, cosmetics, personal care, prescription and medical devices, to the new health frontier of digital-connected devices and algorithm-based diagnostics, SPRIM brings together game-changing science and winning commercial results.
Tikehau Capital is an alternative asset management and investment group with €15.9 billion of assets under management (as at 30 September 2018) and shareholders’ equity of €2.3 billion (as at 30 June 2018). The Group invests in various asset classes (private debt, real estate, private equity and liquid strategies), including through its asset management subsidiary Tikehau IM, on behalf of institutional and private investors. Controlled by its managers, alongside leading institutional partners, Tikehau Capital employs 260 staff (as at 30 September 2018) in its Paris, London, Brussels, Madrid, Milan, New York, Seoul and Singapore offices.
About Objective GI
Objective GI is a clinical research company, launched in 2018 by Colleen Hoke and Don Lazas, MD, whom both recognized a need for high quality, consistent and efficient research programs. The company establishes partnerships with gastroenterology medical practices, providing research infrastructure, optimal trial selection, study implementation and key personnel management to clinical studies. Objective GI’s proprietary processes and technology eliminate the healthcare workflow disruptions typically associated with clinical trials.
For more information, visit https://objectivegi.com.